Rituximab for eradicating inhibitors in people with acquired haemophilia A

Abstract

No randomised clinical trials of rituximab for acquired hemophilia A were found. Thus, based on the highest quality of evidence, we are not able to draw any conclusions or make any recommendations on rituximab for eradicating inhibitors in people with acquired haemophilia A. Given that undertaking randomised controlled trials in this field is a complex task, the authors suggest that, while planning such trials, clinicians treating the disease continue to base their choices on alternative, lower quality sources of evidence. The authors plan, for a future update of this review, to appraise and incorporate any randomised controlled trials, as well as other high-quality non-randomised studies.

Edi̇nsel Hemofi̇li̇ a Deneyi̇mi̇

“…Hemostatik tedavi ve eradikasyon tedavisi ile klinik ve labaratuvar düzelme sağlandı. Rituksimab, FVIII otoantikorlarını yok ederek edinilmiş hemofili tedavisine alternatif bir yaklaşımdır [13]. Olgu 2 ve olgu 3'te siklofosfamid tedavisi altında konjuktival kanama gelişmesi nedeniyle Ritüksimab tedavisine geçildi.…”

Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis

“…“Off label” use of anti-CD20 monoclonal antibody has been studied for patients with acquired hemophilia, showing promising results of durable remission. [ 14 – 16 ] The usual dose is 375 mg/m 2 each week for 4 weeks. Most responses are observed within the first 2 weeks of therapy, with some clinician's inputs, it should be considered in patients resistant to first-line therapy or for those that cannot tolerate standard immunosuppressive therapy.…”